drugset / Trial / NCT05307406
A First-in-Human Study With XAB05 in Healthy Subjects
RandomizedParallel-groupTriple-blindTreatment
Summary
This study is a randomized, placebo-controlled, first in human, single ascending dose Phase 1 study
Timeline
- Start
- 2022-01-24
- Primary completion
- 2022-05-19
- Completion
- 2022-05-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | XAB05 | Unknown | 0.25 mg/kg | Intravenous |
| Subject | XAB05 | Unknown | 20 mg/kg | Intravenous |